Con­nect shrinks time­line for atopic der­mati­tis da­ta; Bi­cy­cle's wheels keep turn­ing with Genen­tech

Con­nect Bio­phar­ma has pushed up the time­line on re­leas­ing topline da­ta for its lead can­di­date, be­ing test­ed in Chi­na, for atopic der­mati­tis. Tar­get­ing the same path­way as megablock­buster Dupix­ent, the biotech will now share re­sults in the sec­ond half of this year, rather than the first half of next year.

The late Mon­day news drop means Con­nect could be on track to file for ap­proval in Chi­na in two years. The topline da­ta from the 16-week in­duc­tion pe­ri­od of the tri­al for CBP-201 will look at 255 pa­tients al­ready en­rolled in­to the study.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER